Synthes to fight off-label promotion charges - UPDATE
This article was originally published in Clinica
Executive Summary
Swiss orthopaedics firm Synthes is to defend itself against a charge of alleged off-label promotion of its Norian XR calcium phosphate bone void filler after the US government hit the firm with an indictment.